Zimmer Biomet’s (ZBH) Buy Rating Reaffirmed at Argus

Posted by Brenda Bartman on Oct 22nd, 2026

Zimmer Biomet (NYSE:ZBH – Get Free Report)‘s stock had its “buy” rating restated by Argus in a research report issued on Thursday, Benzinga reports. They presently have a $125.00 price target on the medical equipment provider’s stock. Argus‘s target price would indicate a potential upside of 26.48% from the stock’s current price.

A number of other analysts have also recently weighed in on the company. BMO Capital Markets reaffirmed a “market perform” rating on shares of Zimmer Biomet in a research report on Monday, September 28th. Truist Financial increased their price objective on Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a report on Thursday, August 6th. Barclays raised Zimmer Biomet to a “hold” rating in a report on Wednesday, October 7th. UBS Group reissued a “buy” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Seven analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $104.47.

Get Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Stock Up 4.2%

Shares of NYSE ZBH traded up $3.97 during mid-day trading on Thursday, reaching $98.83. The company had a trading volume of 2,223,523 shares, compared to its average volume of 2,232,402. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $104.15. The stock has a fifty day moving average of $95.17 and a two-hundred day moving average of $91.47. The company has a market capitalization of $18.85 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 1.81 and a beta of 0.49.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the business earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities research analysts expect that Zimmer Biomet will post 8.54 EPS for the current year.

Insider Transactions at Zimmer Biomet

In related news, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Chad F. Phipps sold 3,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their position. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZBH. Tacita Capital Inc bought a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $26,000. Ancora Advisors LLC acquired a new stake in shares of Zimmer Biomet in the second quarter worth $29,000. Elevation Wealth Partners LLC increased its position in Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 229 shares during the period. Cassaday & Co Wealth Management LLC bought a new position in Zimmer Biomet during the first quarter worth $44,000. Finally, Parvin Asset Management LLC acquired a new position in Zimmer Biomet during the 2nd quarter valued at $47,000. 88.89% of the stock is owned by institutional investors.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.